ACMR vs CLBT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACMR's Piotroski F-Score of 2/9 indicates severe financial distress, with weak operational and profitability health. The Altman Z-Score is unavailable, but the company's negative earnings growth (-77.7% YoY) and declining EPS trend signal deteriorating fundamentals. Despite a strong gross margin (44.39%) and low debt/equity (0.15), the sharp drop in earnings and poor recent earnings surprises (average -20.81% over last 4 quarters) undermine confidence. The stock trades at a premium to its Graham Number ($26.23) and intrinsic value ($9.59), suggesting overvaluation relative to conservative metrics. Insider selling of $16.59M in the last 6 months further reinforces bearish sentiment.
CLBT shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Key strengths include strong valuation and growth metrics. Price trades at a 370.1% premium to fair value estimate ($3.01), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ACMR vs CLBT: Head-to-Head Comparison
This page compares ACM Research, Inc. (ACMR) and Cellebrite DI Ltd. (CLBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.